Thalassemia in Iran: Epidemiology, Prevention, and Management

@article{Abolghasemi2007ThalassemiaII,
  title={Thalassemia in Iran: Epidemiology, Prevention, and Management},
  author={Hassan Abolghasemi and Ali Amid and Sirous Zeinali and Mohammad H. Radfar and Peyman Eshghi and Mohammad Saeid Rahiminejad and Mohammad Ali Ehsani and Hossein Najmabadi and Mohammad Taghi Akbari and Abdolreza Afrasiabi and Haleh Akhavan-Niaki and Hamid Hoorfar},
  journal={Journal of Pediatric Hematology/Oncology},
  year={2007},
  volume={29},
  pages={233-238}
}
PURPOSE To determine the prevalence and geographic distribution of thalassemia and to evaluate the success of the thalassemia prevention and treatment programs in Iran. [] Key MethodMETHODS Data were obtained from the National Thalassemia Registry of Iran, Iranian Blood Transfusion Organization, genetic laboratories involved in prenatal diagnosis, related pharmaceutical companies, and centers performing bone marrow transplantation for thalassemic patients.
Thalassemia in Iran in Last Twenty Years: the Carrier Rates and the Births Trend
TLDR
The authors have tried to address the impacts of prevention efforts in Iran and also the status of new birth cases of thalassemia during the time period ranging from 1989 when the Iranian Thalassemi Society was established to 1995 when the prevention program started to run.
Secular Trends in the National and Provincial Births of New Thalassemia Cases in Iran From 2001 to 2006
TLDR
The main causes were: the at-risk couples not using prenatal diagnosis (PND), marriages before the commencement of Iranian prevention plans, unregistered marriages based on religious conventions, among foreign citizens and the existence of some test errors.
Results of the National Program for Prevention of β-Thalassemia Major in the Iranian Province of Mazandaran
TLDR
In conclusion, at the relatively low cost of premarital screening and genetic counseling, at-risk couples are offered the possibility of preventing the birth of at least 600 undesired TM patients, and a great deal of suffering and an unbearable financial burden has been prevented.
Investigating epidemiologic status of thalassemic patients in Hormozgan province in 2011
TLDR
It seems that the prevention rate of this disease has been low in this province and the instructions essential for birth control has not been provided for families, which requires great care and attention from the authorities in charge.
Chronic disease program in Iran: Thalassemia control program
TLDR
Due to the improvements in the social and economic situation of the people, it seems necessary to focus on prenatal diagnosis and pre-implantation genetic diagnosis (PNG) technique strategies and provide their necessary facilities.
The Iran Thalassemia Prevention Program: Success or Failure?
TLDR
The program has been significantly successful in the reduction of the new thalassemia births, though not in a few provinces like Sistan and Baluchestan, and it needs to be modified to be more compatible with the relevant social textures of different provinces.
Treatment Status of Patients with B-Thalassemia Major in Northern Iran: Thalassemia Registry System
Background: Electronic registry system of beta-thalassemia patients was run by Thalassemia Research Center (TRC) in 2017. The aim of the current study was presentation of therapeutic status in these
β-Thalassemia in Iran: Things Everyone Needs to Know About This Disease
TLDR
Iran has reached an acceptable level of success in thalassemia prevention and the preparation of safe and adequate blood and its achievements can be adapted to other developing countries, particularly in the Middle East.
Causes of Birth of More Than One Thalassemia Major Patient in Families in South-east of Iran: Lessons for Prevention Programs
TLDR
This study showed that in only about 30% of the studied families, the parents were unaware of having thalassemia minor, and in other families, miscellaneous reasons were involved in the birth of the second or subsequent child with TM.
Sistani Population: a Different Spectrum oF β-Thalassemia Mutations From other Ethnic Groups of Iran
TLDR
β-thal mutations are very heterogeneous and significantly different from those found in other parts of Iran and are similar to those of Pakistani and Indian populations and could greatly facilitate timely and accurate PND.
...
...

References

SHOWING 1-10 OF 24 REFERENCES
THE β-THALASSEMIA MUTATION SPECTRUM IN THE IRANIAN POPULATION
TLDR
The results presented here can be used as a basis of prenatal diagnosis of β-thalassemia in different regions of Iran and the relative frequency in the north was much higher than other regions, and it lessened toward the south, where the IVS-I-5(G → C) mutation was more common.
A 12-year preventive program for beta-thalassemia in Northern Sardinia.
TLDR
From 1980 to 1991, 6.3% of the adult population of the province of Sassari, Northern Sardinia, underwent voluntary beta-thalassemia screening, and of the 28,000 subjects examined, 15.7% proved to be heterozygotes for beta-Thalassemia, suggesting that inductive screening played a major role in the efficiency of this preventive beta-halassemia program.
Hematologic and Clinical Responses of Thalassemia Intermedia Patients to Hydroxyurea During 6 Years of Therapy in Iran
TLDR
HU therapy appears to be safe and effective when administered in thalassemic patients to minimize or even obviate the need for regular transfusions and concomitant iron overload, and HU therapy was also associated with a marked increase in hemoglobin, mean corpuscular volume, andmean corpuscular hemoglobin.
Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
TLDR
The good response to HU treatment that a significant number of southwest Iranian patients with beta-thalassemia patients had seems to correlate with particular haplotypes, which indicates that H U treatment is a sensible option for transfusion-dependent beta-thaenasmia patients with a favorable molecular background.
A 12‐year preventive program for β‐thalassemia in Northern Sardinia
TLDR
From 1980 to 1991, 6.3% of the adult population of the province of Sassari, Northern Sardinia, underwent voluntary β‐thalassemia screening, and it is suggested that inductive screening played a major role in the efficiency of this preventive β‐halassemia program.
Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening
TLDR
Molecular determination of genetic markers in early childhood will help to identify candidates for pharmacological HbF switching by HU and reduce the need or cease the PRCT in group A and to increase Hb level and curb the ineffective erythropoesis in group B.
Prognostic factors in bone marrow transplantation for beta thalassemia major: experiences from Iran
TLDR
Increasing age, presence of portal fibrosis and increasing serum ferritin were significantly associated with reduced probability of survival, and the benefits of transplanting more than 5.5 × 108/kg cells in this group of patients with no increase in complications.
Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy
TLDR
Assessment of attitudes of two different haemophilic populations in Iran and Italy towards PND and termination of pregnancy found the greater rate of acceptability of abortion in Iranians may be due to differences in the quality of patient care in the two countries.
Screening for thalassemia: a model of success.
Bone marrow transplantation in thalassaemia patients in Shiraz, Islamic Republic of Iran.
TLDR
It is concluded that allogeneic bone marrow transplantation is an effective therapy for the treatment of beta-thalassaemia major, particularly for patients classified as classes I and II.
...
...